New Findings on Anticoagulation and Afib: Impact on Cognitive Health Revealed
CHICAGO — The BRAIN-AF trial found that anticoagulation with rivaroxaban did not prevent cognitive impairment in individuals with existing atrial fibrillation (Afib). The trial was stopped early due to futility. It showed no significant difference in cognitive decline, stroke, or transient ischemic attack (TIA) between those receiving lower-dose rivaroxaban and those on placebo (7% vs. 6.4%).
The study found that major bleeding was slightly lower in the rivaroxaban group (0.3%) compared to placebo (0.8%), according to Lena Rivard, MD, MSc, of Montreal Heart Institute, presented at the American Heart Association (AHA) annual meeting. The relationship between cognition and Afib remains unclear, with researchers suggesting the need to study other mechanisms like cerebral hypoperfusion.
The study population was young, with an average age of just over 53. Participants included 1,235 Afib patients aged 30-62, with a low stroke risk. The trial excluded individuals with prior strokes, TIAs, or other major health issues.
What were the key findings of the BRAIN-AF trial regarding cognitive impairment in patients with atrial fibrillation?
Interview with Dr. Lena Rivard on the BRAIN-AF Trial Findings
Interviewer: Thank you for joining us, Dr. Rivard. The BRAIN-AF trial recently concluded, and the results might be surprising to many. Could you provide a brief overview of the trial’s main findings?
Dr. Lena Rivard: Certainly. The BRAIN-AF trial aimed to evaluate whether anticoagulation therapy with rivaroxaban could prevent cognitive impairment in patients with atrial fibrillation. Unfortunately, we had to stop the trial early due to futility, as we observed no significant differences in cognitive decline, stroke, or transient ischemic attacks (TIA) between the rivaroxaban group and the placebo group.
Interviewer: That’s quite significant. Can you elaborate on the specific outcomes related to cognitive decline and bleeding risks?
Dr. Lena Rivard: Of course. The overall incidence of cognitive decline was the primary endpoint, and it occurred in 91.4% of participants, which indicates a very high level of cognitive impairment in this population. Interestingly, while stroke incidence was low overall at 0.8%, the rivaroxaban group experienced slightly fewer major bleeding events (0.3%) compared to placebo (0.8%).
Interviewer: The population in this study was relatively young. What impact do you think that had on the results?
Dr. Lena Rivard: The average age of participants was just over 53, which is quite young for a typical atrial fibrillation population. Our cohort consisted of 1,235 individuals aged 30-62, with low stroke risk and no prior strokes or major health issues. Their age and health profiles might play a role in the high percentage of cognitive decline observed, as we didn’t have high-risk factors commonly associated with these outcomes.
Interviewer: The relationship between cognition and atrial fibrillation appears to be complex. What are your thoughts on why the trial did not show the expected results?
Dr. Lena Rivard: The lack of significant findings adds to the ongoing debate regarding the relationship between cognitive decline and atrial fibrillation. We suspect that other mechanisms, such as cerebral hypoperfusion, might be at play. This suggests we need to explore beyond anticoagulation therapies to understand and address cognitive issues in these patients.
Interviewer: You’ve mentioned the importance of using cognitive measures in future trials. How do you think this can change the direction of research in atrial fibrillation?
Dr. Lena Rivard: Absolutely. Based on our findings, I believe future studies should prioritize cognitive assessments as key endpoints. Understanding cognitive outcomes is essential, as it may significantly influence treatment strategies and inform how we approach atrial fibrillation in a comprehensive manner.
Interviewer: Thank you, Dr. Rivard, for your insights on the BRAIN-AF trial. It’s clear that the intersection of cognitive health and atrial fibrillation warrants further exploration.
Dr. Lena Rivard: Thank you for having me. It’s a topic that deserves attention, and I look forward to seeing how future research unfolds in this area.
Participants were randomized to receive either rivaroxaban 15 mg or placebo. The overall incidence of stroke was low (0.8%), while cognitive decline was the most common endpoint (91.4%), followed by stroke (5.1%) and TIA (3.5%). Cognitive assessment relied primarily on the Montreal Cognitive Assessment (MoCA), which raised concerns about the limitations of the study.
The authors suggested that future research should prioritize cognition as a trial endpoint in Afib studies. Researchers also emphasized the importance of incorporating cognitive measures in emerging Afib treatment strategies.